Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BDRX
BDRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BDRX News
Biodexa Secures Exclusive License for Otsuka's OPB-171775, a Novel GIST Treatment
Feb 04 2026
Newsfilter
Biodexa Pharmaceuticals Appoints Fiona Sharp as CFO, Shares Rise 3.45%
Jan 05 2026
NASDAQ.COM
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 16 2025
Benzinga
Mama's Creations Stock Rises Over 13%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 09 2025
Benzinga
Biodexa Activates First European Site for Phase 3 Serenta Trial in FAP
Nov 24 2025
Newsfilter
Biodexa Pharmaceuticals submits $100M shelf registration for versatile securities sales
Sep 26 2025
SeekingAlpha
Biodexa Pharmaceuticals Reports GAAP EPS of £0.00
Sep 12 2025
SeekingAlpha
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Receives Upgrade to Buy: Implications for the Stock
Sep 03 2025
NASDAQ.COM
Biodexa Reports Enrollment of Initial Patients in Key Phase 3 Serenta Trial for Familial Adenomatous Polyposis (FAP)
Aug 18 2025
Newsfilter
ADR Ratio Change Effective
Jul 31 2025
Newsfilter
Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested
Jul 27 2025
TipRanks
ADR Ratio Change
Jul 15 2025
Newsfilter
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Jul 14 2025
Newsfilter
Results of Annual General Meeting
Jun 27 2025
Newsfilter
Biodexa Pharmaceuticals PLC Announces Successful Outcome of Annual General Meeting
Jun 27 2025
NASDAQ.COM
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Jun 25 2025
Newsfilter
Show More News
